Study medicine dosing in children with asthma using inhaler tests
Part of Immune system & allergy, Lungs & breathing clinical trials.
This Phase 2 study checks how glycopyrronium bromide works in children with asthma, including its safety and how well inhaler dosing is tolerated. It also uses breathing tests and inhaler technique checks to confirm your child meets key asthma and lung function requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has asthma confirmed for at least 6 months.
- Your child uses a stable, low-to-medium dose inhaled steroid (ICS) plus one other asthma controller for at least 4 weeks.
- Your child’s breathing test result (FEV1) must fall in a specific range at screening; they must also be able to do spirometry (breathing measurement tests).
- Your child must show asthma improvement after using rescue medicine during a breathing test (a bronchodilator response test).
- A parent/guardian must sign consent (and the child may need to assent) and must attend visits and help complete study diary entries.
- Your child must be able to correctly use specific inhalers used in the study (like Diskus/Accuhaler and Breezhaler).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
This study tests whether adding a medication called glycopyrronium to a common asthma inhaler (BFF) helps children ages 4–12 breathe better. Researchers will measure lung function and compare two different doses of the added medication.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
This trial compares the safety of two different propellants (the gases that push medicine out of inhalers) in people with well-controlled asthma. Researchers want to ensure both propellants are safe to use in asthma inhalers.
This trial tests whether stepping up to either a higher dose of inhaled steroid/long-acting bronchodilator or a special fine-particle triple therapy (which includes an extra medication) can improve small-airway health in people whose asthma is still not well controlled on a medium-dose combination.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.